Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Follow-Up Plasma Apolipoprotein E Levels In The Australian Imaging, Biomarkers And Lifestyle Flagship Study Of Ageing (Aibl) Cohort, Veer B. Gupta, V.B, Andrea C. Wilson, Samantha Burnham, Eugene Hone, Steve Pedrini, Simon M. Laws, Wei L.F. Lim, Alan Rembach, Stephanie Rainey-Smith, David Ames, Lynne Cobiac, S L. Macaulay, Colin L. Masters, Christopher C. Rowe, Ashley I. Bush, Ralph Martins, Aibl Research Group
Follow-Up Plasma Apolipoprotein E Levels In The Australian Imaging, Biomarkers And Lifestyle Flagship Study Of Ageing (Aibl) Cohort, Veer B. Gupta, V.B, Andrea C. Wilson, Samantha Burnham, Eugene Hone, Steve Pedrini, Simon M. Laws, Wei L.F. Lim, Alan Rembach, Stephanie Rainey-Smith, David Ames, Lynne Cobiac, S L. Macaulay, Colin L. Masters, Christopher C. Rowe, Ashley I. Bush, Ralph Martins, Aibl Research Group
Research outputs 2014 to 2021
Introduction: Alzheimer's disease (AD) is a growing socioeconomic problem worldwide. Early diagnosis and prevention of this devastating disease have become a research priority. Consequently, the identification of clinically significant and sensitive blood biomarkers for its early detection is very important. Apolipoprotein E (APOE) is a well-known and established genetic risk factor for late-onset AD; however, the impact of the protein level on AD risk is unclear. We assessed the utility of plasma ApoE protein as a potential biomarker of AD in the large, well-characterised Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL) cohort. Methods: Total plasma ApoE levels were …
Guidelines For The Standardization Of Preanalytic Variables For Blood-Based Biomarker Studies In Alzheimer's Disease Research, Sid O'Bryant, Veer Gupta, Kim Henriksen, Melissa Edwards, Andreas Jeromin, Simone Lista, Chantal Bazenet, Holly Soares, Simon Lovestone, Harald Hampel, Thomas Montine, Kaj Blennow, Tatiana Foroud, Maria Carrillo, Neill Graff-Radford, Christoph Laske, Monique Breteler, Leslie Shaw, John Q. Trojanowski, Nicole Schupf, Robert A. Rissman, Anne M. Fagan, Pankaj Oberoi, Robert Umek, Michael W. Weiner, Paula Grammas, Holly Posner, Ralph Martins
Guidelines For The Standardization Of Preanalytic Variables For Blood-Based Biomarker Studies In Alzheimer's Disease Research, Sid O'Bryant, Veer Gupta, Kim Henriksen, Melissa Edwards, Andreas Jeromin, Simone Lista, Chantal Bazenet, Holly Soares, Simon Lovestone, Harald Hampel, Thomas Montine, Kaj Blennow, Tatiana Foroud, Maria Carrillo, Neill Graff-Radford, Christoph Laske, Monique Breteler, Leslie Shaw, John Q. Trojanowski, Nicole Schupf, Robert A. Rissman, Anne M. Fagan, Pankaj Oberoi, Robert Umek, Michael W. Weiner, Paula Grammas, Holly Posner, Ralph Martins
Research outputs 2014 to 2021
The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood-based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and cerebrospinal fluid biomarker approaches. Despite the fact that preanalytical processing is the largest source of variability in laboratory testing, there are no currently available standardized preanalytical guidelines. The current international working group provides the initial starting point for such guidelines for standardized operating procedures (SOPs). It is anticipated that these guidelines will be updated as additional research findings become available. The statement …